Wed, Aug 20, 2014, 4:01 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

jeremiahthirtythreeone 11 posts  |  Last Activity: Jul 10, 2014 3:54 PM Member since: Feb 16, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Nothing new in these articles. The significance is that Belviq will continue to get more and more exposure in the medical literature

    New pharmacological treatments for the management of obesity.
    Hurt RT, Edakkanambeth Varayil J, Ebbert JO - Curr Gastroenterol Rep - Jun 2014; 16(6); 394

    Abstract
    Obesity is quickly becoming the leading preventable cause of death in the USA. Over 60 obesity-related comorbidities exist which increase the complexity and cost of medical care in obese patients. Even a moderate weight loss of 5 % can reduce morbidity associated with these conditions. Lifestyle modification through caloric restriction and enhanced exercise and physical activity remain the first line treatment for obesity. The development of pharmacologic agents for the treatment of obesity has been challenged by both lack of efficacy and serious adverse side effects leading to their removal from market. Two new agents were recently approved by the US Food and Drug Administration to complement lifestyle modification in obese and overweight patients and one obesity-related comorbidity). Lorcaserin is a novel serotonin 5-HT2C selective agonist which has been shown in three phase III studies to significantly reduce weight and cardiovascular risk factors such as diabetes. Phent/topiramate extended release (ER) is a novel combination of two agents which have individually been shown to significantly reduce weight. The combination agent phent/topiramate ER has been shown to reduce weight in overweight and obese subjects in a number of studies. This article reviews the pharmacology, clinical efficacy, and safety of these new agents compared to past and other presently available medications for the treatment of obesity.

    NOTE: "Lorcaserin....shown to significantly reduce weight and cardiovascular risk factors such as diabetes."

    This is a factual statement that will continue to increase in its dissemination...because the science will prevail.

    CONTINUED

    Daniel
    UCLA MD

    Sentiment: Strong Buy

  • jeremiahthirtythreeone by jeremiahthirtythreeone May 26, 2014 7:58 PM Flag

    Direct-to-consumer advertising of prescriptions impacts patient requests

    Publish date: MAY 23, 2014

    Published on Medical Economics (medicaleconomics.modernmedicineDOTcom)
    By: Keith Griffin

    The influx of new patients under the Affordable Care Act (ACA) may exacerbate an ongoing challenge for physicians: Responding to patient inquiries and requests for prescriptions in the wake of large-scale, direct-to-consumer pharmaceutical advertising campaigns. Physician experts say there are strategies practices can use to talk with patients about medication choices.
    On one side of the direct-to-consumer advertising debate are doctors, who can be overwhelmed by patient demands for specific medications while trying to communicate effectively with a patient during a short encounter. On the other side is the pharmaceutical industry trying to educate patients, build awareness, and drive sales in a tightly-regulated and competitve industry.
    Since 1997, when the U.S. Food and Drug Administration issued guidance to enable pharmaceutical companies to more easily advertise to the public on television, companies have spent billions annually on these consumer marketing efforts. As a November 2013 article in the American Medical Association Journal of Ethics concluded: “Drug advertisements remain pervasive and therefore exert an undeniable influence on the way the public learns about available therapies and how patients and physicians communicate.”
    One-third of individuals who see a direct-to-consumer television ad, if it’s relevant to their condition, will ask doctors to prescribe that drug, and more than one-half of physicians will prescribe it, according to a national survey by USA Today, the Kaiser Family Foundation and the Harvard School of Public Health published in 2008.

    CONTINUED
    Daniel
    UCLA MD

    Sentiment: Strong Buy

  • jeremiahthirtythreeone jeremiahthirtythreeone May 26, 2014 8:06 PM Flag

    “It’s much easier to write [the prescription] instead of spending five minutes explaining why a different drug is better than what’s on the market,” says Jeffrey Lobosky, MD, an associate clinical professor in the department of neurological surgery at the University of California-San Francisco.
    Molly Cooke, MD, immediate past president of the American College of Physicians, says that while advertising is described as patient education, “the commitment to education” is not uniform across medications. For example, she says there is not much emphasis on common drugs. Instead, the companies stress newer, more expensive drugs still covered by patents. “This is a genie that’s notv going to get put back in the bottle,” Cooke says

    AFFORDABLE CARE ACT impact
    The ACA likely will bring new patients into practices who haven’t been getting care, and medication questions related to advertising may become more frequent as physicians begin treating these patients. Physicians need to ensure that these medication inquiries are not a distraction from more critical topics.
    The challenge is that answering these inquires takes time—the most precious resource the patient has when he or she is in your practice, says the ACP’s Cooke. Spending five minutes of a 15-minute patient encounter explaining why a new weight loss medication may not be right for them “is five minutes I can’t spend on something else.”

    Daniel
    UCLA MD

    Sentiment: Strong Buy

  • jeremiahthirtythreeone jeremiahthirtythreeone Jul 10, 2014 3:54 PM Flag

    This study was based on the BLOOM DM findings.
    Nearly twice as many patients with diabetes in the lorcaserin group achieved hemoglobin levels of less than 7% compared with the placebo group (50.4% vs. 26.3%), even if they did not lose weight, the researchers found.

    This important and should continue to be emphasized by Eisai.

    Daniel
    UCLA MD

    Sentiment: Strong Buy

  • jeremiahthirtythreeone jeremiahthirtythreeone May 30, 2014 11:35 AM Flag

    None that I know of!!! Now there are some that are being introduced that combine two antihypoglycemics for the treatment of type 2 DM but I can think of no others but this usually combines one new drug with a generic. It is hard two understand why two generics would not be preferred over an expensive formulation with two generics. Go figure! All I know is that our medical group always prefers generics whenever its possible.

    Daniel
    UCLA MD

    Sentiment: Strong Buy

  • jeremiahthirtythreeone jeremiahthirtythreeone May 30, 2014 11:19 AM Flag

    YMB deleted the second article but it pretty much says the same thing. Here is the reference

    New centrally acting agents for appetite control: from biological mechanisms to clinical efficacy.
    Catoira NP, Viale L, Di Girolamo G, Gonzalez C - Curr Med Res Opin - Jun 2014; 30(6); 961-9

    CONCLUSION:

    Conclusion: With differences in efficacy (higher for the topiramate-phent combination), both preparations are active in reducing appetite and body weight, as well as in improving comorbidities. Additional information will be collected from Phase IV surveillance. Focus on cardiovascular, neuropsychiatric (for both introductions) and embrio-fetal safety (especially for topiramate) is expected.

    Sentiment: Strong Buy

  • jeremiahthirtythreeone jeremiahthirtythreeone May 30, 2014 2:28 PM Flag

    Thanks hedge. I also appreciate your input since it seems clear to me you have a sound understanding of the financial market. This helps me understand things better.

    Daniel
    UCLA MD

    Sentiment: Strong Buy

  • jeremiahthirtythreeone jeremiahthirtythreeone May 30, 2014 11:23 AM Flag

    Norrie this is becoming too obvious. It is incredible all the nonsensical information that is allowed. Nevertheless, after having the second article deleted as a stand alone post I was able to post the reference on my original post.

    Norrie thanks for all that you do to try to ward off the falsehoods on this board.

    Daniel
    UCLA MD

    Sentiment: Strong Buy

  • jeremiahthirtythreeone jeremiahthirtythreeone May 30, 2014 12:04 PM Flag

    dio
    This is an extremely point that none of the articles bring up and relevant to the discussion of efficacy between the two. I know of very few other than yourself that has recognized this big discrepancy in the efficacy of V. Very important to always bring to the forefront.

    Daniel
    UCLA MD

    Sentiment: Strong Buy

  • jeremiahthirtythreeone jeremiahthirtythreeone May 30, 2014 11:31 AM Flag

    VJ
    Yes, I will continue to post relevant information. I hope the importance of increasing exposure in the medical literature is appreciated and especially when the it is presented in a positive light.
    Daniel
    UCLA MD

    Sentiment: Strong Buy

  • jeremiahthirtythreeone jeremiahthirtythreeone May 30, 2014 2:31 PM Flag

    JD things are still pretty busy. Will email you this weekend to catch up.
    Danny

    Daniel
    UCLA MD

    Sentiment: Strong Buy

ARNA
4.230.00(0.00%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.